Rocket Doctor AI Inc., a physician-built digital health company operating at the intersection of artificial intelligence and virtual care, is stepping up its market visibility.

The company (CSE: AIDR; OTC: AIRDF; Frankfurt: 939) announced it has engaged Vancouver-based Danayi Capital Corp. to provide digital marketing services over a two-month period starting February 9, 2026. The agreement comes with an upfront payment of USD $125,000 and is focused on online investor outreach and digital advertising via WallStreetLogic.com.

While short in duration, the move signals a broader push by Rocket Doctor AI to sharpen its narrative with investors and the market—particularly as competition intensifies across AI-enabled healthcare platforms.

A targeted marketing push, not a speculative play

According to the company, Danayi will operate strictly as a third-party service provider. The firm holds no direct or indirect ownership in Rocket Doctor AI or its securities, and all parties are described as operating at arm’s length.

That distinction matters. In today’s small-cap and emerging-tech markets, marketing engagements often attract scrutiny from regulators and investors alike. Rocket Doctor’s disclosure—covering Danayi’s compensation, scope of work, and lack of equity interest—reads like a preemptive move to reinforce transparency.

The marketing effort will focus on digital campaigns and online advertising, an increasingly common tactic among health-tech firms looking to stand out in crowded capital markets without resorting to splashy product announcements.

Equity incentives signal continued reliance on external expertise

Alongside the marketing engagement, Rocket Doctor AI also disclosed new equity compensation grants to consultants.

The company issued:

• 33,353 stock options, exercisable at $0.77 per share, with a three-year term

• 205,065 restricted share units (RSUs), also valid for three years

Both the options and RSUs vest over one year and were granted under the company’s existing share compensation plans.

While modest in size, the grants point to Rocket Doctor’s ongoing reliance on external consultants—a common approach among growth-stage AI and healthcare firms balancing speed, specialization, and cost control. Rather than expanding headcount aggressively, many companies in this space are opting for flexible, incentive-aligned expertise.

Why this matters in the AI health market

Digital health is no longer just about virtual visits. The sector is shifting toward AI-powered decision support, automation, and scalable care delivery—areas where Rocket Doctor AI is positioning itself aggressively.

At the center of the company’s technology stack is its Global Library of Medicine (GLM), a clinically validated AI decision-support system developed with input from hundreds of physicians worldwide. Unlike consumer-facing symptom checkers, GLM is positioned as a professional-grade tool designed to support clinical judgment rather than replace it.

That physician-first framing is increasingly important. As regulators and healthcare systems scrutinize AI tools for safety and bias, platforms built with direct clinician involvement are gaining credibility over black-box alternatives.

Beyond AI: a full-stack virtual care platform

Rocket Doctor AI’s ambitions extend beyond algorithms. Through Rocket Doctor Inc., the company operates an AI-powered digital health platform and marketplace designed to help physicians launch and manage independent virtual or hybrid practices.

To date, the platform has supported:

• 300+ licensed physicians

• 700,000+ patient visits

The value proposition is straightforward but timely: reduce administrative burden, restore physician autonomy, and expand patient access—particularly in underserved regions.

In Canada, that means rural and remote communities with limited access to family doctors. In the U.S., it includes patients covered by Medicaid and Medicare, where provider shortages and reimbursement complexity often limit care options.

Marketing meets mission

The decision to invest in digital marketing comes as healthcare AI companies face a dual challenge: proving clinical value while also communicating that value clearly to investors, partners, and regulators.

Rocket Doctor AI’s technology story—AI decision support, large language models, connected medical devices—sits squarely within some of the most hyped (and scrutinized) areas of modern healthcare. Cutting through the noise requires not just innovation, but disciplined messaging.

By engaging Danayi Capital for a defined, short-term campaign, Rocket Doctor appears to be testing how targeted digital outreach can amplify its story without overcommitting resources.

A crowded field with rising stakes

Rocket Doctor AI is far from alone in this race. Teladoc, Amwell, and a wave of AI-native startups are all vying to define the next generation of virtual care. Meanwhile, Big Tech continues to circle healthcare with AI-powered tools, raising the bar for differentiation.

In that context, visibility matters. Not just with patients or providers, but with capital markets increasingly selective about which AI narratives they believe.

The company’s recent disclosures suggest a strategy focused on incremental execution rather than headline-grabbing moves—tight marketing windows, measured equity incentives, and a steady emphasis on physician-led design.

The takeaway

Rocket Doctor AI’s engagement of Danayi Capital may not be transformative on its own, but it reflects a broader reality of the AI healthcare market in 2026: innovation alone isn’t enough. Companies must also prove credibility, transparency, and momentum.

As AI continues to reshape healthcare delivery, the winners are likely to be those that balance technical ambition with disciplined growth—and know how to tell that story clearly.

Get in touch with our MarTech Experts.